Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 640 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR A call to action: how our Campaigns Ambassadors are shaping the... May 6, 2022 New tool to tackle gaps in public’s knowledge of blood cancer... July 14, 2023 ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... June 5, 2023 How I Coped With My Own Cancer Diagnoses As an Oncologist October 13, 2022 Load more HOT NEWS ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib Teacher on Leave for Breast Cancer Treatment Forced to Pay for... FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction...
